CN109641897A - Bcl-2选择性抑制剂及其制备和用途 - Google Patents

Bcl-2选择性抑制剂及其制备和用途 Download PDF

Info

Publication number
CN109641897A
CN109641897A CN201780053177.XA CN201780053177A CN109641897A CN 109641897 A CN109641897 A CN 109641897A CN 201780053177 A CN201780053177 A CN 201780053177A CN 109641897 A CN109641897 A CN 109641897A
Authority
CN
China
Prior art keywords
base
methyl
added
pyridine
methylene chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780053177.XA
Other languages
English (en)
Other versions
CN109641897B (zh
Inventor
王虎庭
朱岩
商现星
张久庆
胡远东
何伟男
张慧
张淑远
侯登
刘琦超
彭勇
韩永信
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centaurus Biopharma Co Ltd
Shouyao Holdings Beijing Co Ltd
Original Assignee
Shouyao Holdings Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201610800391.4A external-priority patent/CN107793412A/zh
Priority claimed from CN201710604198.8A external-priority patent/CN109293656A/zh
Application filed by Shouyao Holdings Beijing Co Ltd filed Critical Shouyao Holdings Beijing Co Ltd
Publication of CN109641897A publication Critical patent/CN109641897A/zh
Application granted granted Critical
Publication of CN109641897B publication Critical patent/CN109641897B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

公开了式(I)所示的化合物：

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201780053177.XA 2016-09-01 2017-09-01 Bcl-2选择性抑制剂及其制备和用途 Active CN109641897B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016108003914 2016-09-01
CN201610800391.4A CN107793412A (zh) 2016-09-01 2016-09-01 Bcl‑2选择性抑制剂及其制备和用途
CN201710604198.8A CN109293656A (zh) 2017-07-24 2017-07-24 Bcl-2选择性抑制剂及其制备和用途
CN2017106041988 2017-07-24
PCT/CN2017/100226 WO2018041248A1 (zh) 2016-09-01 2017-09-01 Bcl-2选择性抑制剂及其制备和用途

Publications (2)

Publication Number Publication Date
CN109641897A true CN109641897A (zh) 2019-04-16
CN109641897B CN109641897B (zh) 2021-12-07

Family

ID=61300127

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780053177.XA Active CN109641897B (zh) 2016-09-01 2017-09-01 Bcl-2选择性抑制剂及其制备和用途

Country Status (2)

Country Link
CN (1) CN109641897B (zh)
WO (1) WO2018041248A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018127130A1 (en) * 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
HRP20221158T1 (hr) 2017-04-18 2022-12-09 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva za izazivanje apoptoze
SG11202009933WA (en) 2018-04-29 2020-11-27 Beigene Ltd Bcl-2 INHIBITORS
CA3117849A1 (en) 2018-10-29 2020-05-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor
CN111747949B (zh) * 2019-03-29 2022-07-01 首药控股(北京)股份有限公司 Bcl-2选择性抑制剂的制备方法
US20220388977A1 (en) * 2019-06-14 2022-12-08 Beijing Shenogen Pharma Group Ltd. Shp2 phosphatase allosteric inhibitor
CN114057728A (zh) 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448959A (zh) * 2009-05-26 2012-05-09 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN103153993A (zh) * 2010-05-26 2013-06-12 Abbvie公司 治疗癌症和免疫与自身免疫疾病的细胞程序死亡诱导药剂
CN105026394A (zh) * 2013-03-14 2015-11-04 艾伯维公司 用于治疗癌症和免疫性和自身免疫性疾病的细胞凋亡诱导剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448959A (zh) * 2009-05-26 2012-05-09 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN103153993A (zh) * 2010-05-26 2013-06-12 Abbvie公司 治疗癌症和免疫与自身免疫疾病的细胞程序死亡诱导药剂
CN105026394A (zh) * 2013-03-14 2015-11-04 艾伯维公司 用于治疗癌症和免疫性和自身免疫性疾病的细胞凋亡诱导剂

Also Published As

Publication number Publication date
WO2018041248A1 (zh) 2018-03-08
CN109641897B (zh) 2021-12-07

Similar Documents

Publication Publication Date Title
CN109641897A (zh) Bcl-2选择性抑制剂及其制备和用途
CN104860941B (zh) 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN103917525B (zh) Lrrk2激酶活性的抑制剂
CN106715440B (zh) 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
CN111886219A (zh) 免疫抑制剂及其制备方法和在药学上的应用
CN110312716A (zh) 双环oga抑制剂化合物
WO2018171633A1 (zh) 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
TW200829567A (en) Certain substituted amides, method of making, and method of use thereof
TW202014423A (zh) 吲哚類大環衍生物、其製備方法及其在醫藥上的應用
CN111793068A (zh) 杂芳基化合物和其用途
CN110678461B (zh) Syk抑制剂及其使用方法
CN102036967A (zh) 作为5-ht6拮抗剂的芳基磺酰基吡唑啉甲脒衍生物
TWI452044B (zh) 嗎啉衍生物
CN111867585A (zh) 噁二唑瞬时受体电位通道抑制剂
TW202003495A (zh) 苯並哌啶或雜芳基並哌啶類衍生物、其製備方法及其在醫藥上的應用
WO2020233641A1 (zh) 用作ret激酶抑制剂的化合物及其应用
TW201625533A (zh) Ｋｃｎｑ ２至５通道活化劑
CN109689645A (zh) 作为nik抑制剂的氰基吲哚啉衍生物
WO2021238827A1 (zh) Egfr抑制剂、其制备方法及用途
TW202106693A (zh) 吲哚類大環衍生物、其製備方法及其在醫藥上的應用
WO2022166860A1 (zh) Pim激酶抑制剂
WO2022166741A1 (zh) 含有苯并杂环的作为egfr激酶抑制剂的大环化合物、其药物组合物和用途
WO2020011220A1 (zh) 杂芳基类衍生物、其制备方法及其在医药上的应用
CN106117182A (zh) 喹唑啉‑n‑苯乙基四氢异喹啉类化合物及其制备方法和应用
CN112334461A (zh) Oga抑制剂化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant